汇宇制药：子公司参与全国药品集中采购拟中选

Core Viewpoint - The company, Huilong Pharmaceutical, announced its subsidiary's participation in the 11th national centralized drug procurement organized by the National Drug Procurement Office, with one product, Meisobam Injection, expected to win the bid [1] Group 1 - The company’s subsidiary, Sichuan Huilong Haiyue Pharmaceutical Technology Co., Ltd., is involved in the bidding process for centralized drug procurement [1] - The product Meisobam Injection is anticipated to be awarded in this procurement round [1] - The product is expected to receive its drug registration certificate from the National Medical Products Administration in October 2024, and has not generated any sales revenue prior to this bid [1]